Indicators
Indicators
Value
Direction
MACD(12,26,9)
-1.658
Sell
RSI(14)
33.402
Neutral
STOCH(KDJ)(9,3,3)
8.775
Oversold
ATR(14)
2.185
High Vlolatility
CCI(14)
-106.027
Sell
Williams %R
89.197
Oversold
TRIX(12,20)
-0.242
Sell
StochRSI(14)
100.000
Buy
Boston Scientific Corp
BSX91.910USD
-0.670-0.72%
Market hours （ET）Quotes delayed by 15 min
136.24BMarket Cap
48.68P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Boston Scientific Corp
Currency: USD Updated: 2025-12-12Key Insights
Boston Scientific Corp's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 20/208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 125.29.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Boston Scientific Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
36
analysts
Buy
Current Rating
125.291
Target Price
+33.52%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Boston Scientific Corp Highlights
StrengthsRisks
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 32.05% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 16.75B.
Undervalued
The company’s latest PE is 49.04, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.40B shares, decreasing 0.03% quarter-over-quarter.
Held by HACAX
Star Investor HACAX holds 21.57K shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-12The current financial score of Boston Scientific Corp is 8.85, ranking 26/208 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 5.07B, representing a year-over-year increase of 20.34%, while its net profit experienced a year-over-year increase of 60.98%.
Score
Financials
7.55
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
9.04
Operational Efficiency
9.95
Growth Potential
10.00
Shareholder Returns
7.70
Boston Scientific Corp's Company Valuation
Currency: USD Updated: 2025-12-12The current valuation score of Boston Scientific Corp is 5.88, ranking 183/208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 49.04, which is 125.37% below the recent high of 110.52 and 0.90% above the recent low of 48.60.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 20/208
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-12The current earnings forecast score of Boston Scientific Corp is 8.67, ranking 18/208 in the Healthcare Equipment & Supplies industry. The average price target for Boston Scientific Corp is 127.00, with a high of 140.00 and a low of 101.45.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
36
analysts
Buy
Current Rating
125.291
Target Price
+33.52%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
90
Total
4
Median
7
Average
Company name
Ratings
Analysts
Boston Scientific Corp
BSX
36
Intuitive Surgical Inc
ISRG
34
Edwards Lifesciences Corp
EW
34
Veeva Systems Inc
VEEV
34
Thermo Fisher Scientific Inc
TMO
27
Danaher Corp
DHR
26
1
2
3
...
18
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-12The current price momentum score of Boston Scientific Corp is 6.67, ranking 148/208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 100.98 and the support level at 87.81, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
92.680
Sell
MA10
95.724
Sell
MA20
97.667
Sell
MA50
98.787
Sell
MA100
100.963
Sell
MA200
101.191
Sell
Institutional Confidence
Currency: USD Updated: 2025-12-12The current institutional shareholding score of Boston Scientific Corp is 10.00, ranking 1/208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 94.34%, representing a quarter-over-quarter decrease of 0.24%. The largest institutional shareholder is The Vanguard, holding a total of 137.57M shares, representing 9.28% of shares outstanding, with 2.50% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Fidelity Management & Research Company LLC
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
Geode Capital Management, L.L.C.
Capital World Investors
Managed Account Advisors LLC
The Bollard Group, LLC
Norges Bank Investment Management (NBIM)
1
2
Risk Assessment
Currency: USD Updated: 2025-12-12The current risk assessment score of Boston Scientific Corp is 9.53, ranking 6/208 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.67. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.68
VaR
+2.07%
240-Day Maximum Drawdown
+15.52%
240-Day Volatility
+28.27%
Return
Best Daily Return
60 days
+3.95%
120 days
+4.46%
5 years
+6.76%
Worst Daily Return
60 days
-3.77%
120 days
-3.77%
5 years
-8.93%
Sharpe Ratio
60 days
-1.08
120 days
-0.91
5 years
+0.95
Risk Assessment
Maximum Drawdown
240 days
+15.52%
3 years
+15.52%
5 years
+25.18%
Return-to-Drawdown Ratio
240 days
+0.14
3 years
+2.15
5 years
+1.07
Skewness
240 days
-0.55
3 years
-0.28
5 years
-0.16
Volatility
Realised Volatility
240 days
+28.27%
5 years
+24.75%
Standardised True Range
240 days
+2.41%
5 years
+1.37%
Downside Risk-Adjusted Return
120 days
-146.32%
240 days
-146.32%
Maximum Daily Upside Volatility
60 days
+15.81%
Maximum Daily Downside Volatility
60 days
+19.90%
Liquidity
Average Turnover Rate
60 days
+0.49%
120 days
+0.52%
5 years
--
Turnover Deviation
20 days
-11.06%
60 days
+8.05%
120 days
+14.61%
Peer Comparison
Healthcare Equipment & Supplies
Boston Scientific Corp
BSX
8.12 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
LNTH
8.62 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
LivaNova PLC
LIVN
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Becton Dickinson and Co
BDX
8.46 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Tactile Systems Technology Inc
TCMD
8.43 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Align Technology Inc
ALGN
8.39 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Boston Scientific Corp?
The TradingKey Stock Score provides a comprehensive assessment of Boston Scientific Corp based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Boston Scientific Corp’s performance and outlook.
How do we generate the financial health score of Boston Scientific Corp?
To generate the financial health score of Boston Scientific Corp, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Boston Scientific Corp's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Boston Scientific Corp.
How do we generate the company valuation score of Boston Scientific Corp?
To generate the company valuation score of Boston Scientific Corp, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Boston Scientific Corp’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Boston Scientific Corp’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Boston Scientific Corp.
How do we generate the earnings forecast score of Boston Scientific Corp?
To calculate the earnings forecast score of Boston Scientific Corp, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Boston Scientific Corp’s future.
How do we generate the price momentum score of Boston Scientific Corp?
When generating the price momentum score for Boston Scientific Corp, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Boston Scientific Corp’s prices. A higher score indicates a more stable short-term price trend for Boston Scientific Corp.
How do we generate the institutional confidence score of Boston Scientific Corp?
To generate the institutional confidence score of Boston Scientific Corp, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Boston Scientific Corp’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Boston Scientific Corp.
How do we generate the risk management score of Boston Scientific Corp?
To assess the risk management score of Boston Scientific Corp, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Boston Scientific Corp’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Boston Scientific Corp.
